Physician profile
Eric S Knochenhauer
NPI 1295749430
$1,195.03
in general payments reported to CMS, 2019-2025
11 companies · $158 in 2025
The $158 reported for 2025 was more than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $115 · 2021: $148 · 2022: $168 · 2023: $135 · 2024: $215 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $508.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $475.77 | 2019-2025 | Menopur |
| Vitrolife INC. | $163.21 | 2019 | |
| Astellas Pharma US INC | $161.33 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $132.83 | 2023-2025 | Myfembree |
| Emd Serono, INC. | $69.22 | 2019-2020 | |
| Myovant Sciences INC. | $66.18 | 2022 | |
| Abbvie INC. | $58.76 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $31.94 | 2020-2021 | |
| Coopersurgical, INC. | $18.52 | 2022 | |
| Pfizer INC. | $17.27 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Knochenhauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.